Imperial College London


Faculty of MedicineNational Heart & Lung Institute

Honorary Clinical Lecturer



+44 (0)20 3313 1677v.libri




NIHR Imperial Clinical Research FacilityICTEM buildingHammersmith Campus





Vincenzo Libri is a Clinical Senior Lecturer within the Division of Investigative Science at Imperial College London and Head of Clinical Studies at the ‘Sir John McMichael’ Clinical Research Centre - Hammersmith Campus. He also coordinates a MRes in Translational Medicine for graduates in medicine and basic scientists with a degree in life sciences.

From 1990 to 1998 he was a Welcome Trust and Medical Research Council Grant Holder at the School of Pharmacy, University of London (UK). In 1994 he was appointed Lecturer in Clinical Pharmacology at the University of Rome, (Italy). In the last ten years, Vincenzo has worked in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly, and GlaxoSmithKline) undertaking direct responsibilities for phase I/II clinical trials. In 2004 he was appointed Head of Experimental and Translational Medicine at the Department of Clinical Pharmacology and Discovery Medicine, Neurology CEDD, GSK-UK.

Dr Libri joined Imperial College in April 2009 to lead a team of clinicians, nurses and administrative staff and coordinate the development of a sustainable portfolio of clinical trials and experimental medicine studies across therapeutic areas. He is a Principal Investigator for the development and implementation of Phase I/II clinical trials in healthy volunteers and patients, with primary interests in experimental neurology, translational medicine and clinical neuro-pharmacology.



Voysey M, Clemens SAC, Madhi SA, et al., 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, The Lancet, Vol:397, ISSN:0140-6736, Pages:881-891

Voysey M, Clemens SAC, Madhi SA, et al., 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, The Lancet, Vol:397, ISSN:0140-6736, Pages:99-111

Mullin S, Smith L, Lee K, et al., 2020, Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial., Jama Neurol, Vol:77, Pages:427-434

Reetz K, Hilgers R-D, Isfort S, et al., 2019, Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA), Neurological Research and Practice, Vol:1, ISSN:2524-3489

Mauricio R, Benn C, Davis J, et al., 2019, Tackling gaps in developing life-changing treatments for dementia., Alzheimers Dement (n Y), Vol:5, Pages:241-253

More Publications